Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Cancer Res. 2020 Dec 22;27(5):1463–1475. doi: 10.1158/1078-0432.CCR-20-3555

Figure 1. Tarloxotinib-E inhibits ErbB family member phosphorylation and downstream signaling in EGFR-, HER2- or NRG1-driven cell lines.

Figure 1.

Cells were treated with the indicated doses (nmo/L) of afatinib, gefitinib, osimertinib or tarloxotinib-E (active drug) for 2 hours, lysed and analyzed by immunoblot for the indicated proteins. A) CUTO14 cell line (EGFR exon 20 insertion mutation). B) H1781 (HER2 exon 20 insertion mutation). C) MDA-MB-175vII (NRG1 fusion cell line). Representative images of blots are shown. Experiments were performed in triplicate.